CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.
Morningstar11d
Demand for CSL’s Plasma Products Persists as Supply Improves
CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...
Hosted on MSN4d
CSL’s mixed half-year: plasma strength offsets vaccine weakness, bright outlook maintained
CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, ...
Investing10d
CSL lifts HY profit as plasma sales jump, offsets flu vaccine weakness
CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...
Falling US flu vaccine rates hurt Australia's CSL profit growth
Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...
Morningstar11d
CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business — Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...